| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9018e575c930fa852fd6d8cdfee3d41a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3dd543259881a2803432b8fa3f6c1161
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_272ea18b3dd4d594d378c254e901a449
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f71d4dc5ed0705923000f69ed0da2925 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-04 |
| filingDate |
2004-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a704d3406e9f8ee99f975230c7cdca54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41c5ba96e37875b142becaf2012c49fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e14321b3237d6216f3fe537d79dedf49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5e7ec4ff641bbc5ac28e6ed662c9d2e |
| publicationDate |
2009-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7588903-B2 |
| titleOfInvention |
Use of isogenic drug-resistant cell lines to determine the sequence of chemotherapeutic drug treatment |
| abstract |
The present invention provides a method for determining a sequence to administer multiple types of chemotherapeutic drugs for killing cancerous cells to reduce the induction of drug cross-resistance in a patient. The methods also involves screening drug candidates to select a lead anticancer drug from amongst a plurality of candidate drugs, the lead having a reduced capacity to induce cross resistance in a patient against one or more known anticancer drugs, and all of the drugs having the ability to kill cancerous cells of the same selected tumour type. Moreover, the methods involve determining a sequence to administer multiple types of cytotoxic drugs for killing undesired cells to reduce the induction of drug cross-resistance in the cells. |
| priorityDate |
2003-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |